Related references
Note: Only part of the references are listed.The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram
Wei-Li Kuan et al.
PSYCHOPHARMACOLOGY (2008)
RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease
Stephen J. Gold et al.
JOURNAL OF NEUROSCIENCE (2007)
The partial 5-HT1A agonist buspirone reduces the expression and development of I-DOPA-induced dyskinesia in rats and improves I-DOPA efficacy
Karen L. Eskow et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2007)
Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease
Thomas Carlsson et al.
JOURNAL OF NEUROSCIENCE (2007)
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in Parkinsonian rats
Manolo Carta et al.
BRAIN (2007)
Sarizotan as a treatment for dyskinesias in Parkinson's disease:: A double-blind placebo-controlled trial
Christopher G. Goetz et al.
MOVEMENT DISORDERS (2007)
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\increased motor disability
Mahmoud M. Iravani et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Post-versus presynaptic plasticity in L-DOPA-induced dyskinesia
M. Angela Cenci et al.
JOURNAL OF NEUROCHEMISTRY (2006)
5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease
Erwan Bezard et al.
NEUROBIOLOGY OF DISEASE (2006)
Tryptophan-deficient diet increases the neurochemical and behavioral response to amphetamine
Manolo Carta et al.
BRAIN RESEARCH (2006)
A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia
F Gardoni et al.
JOURNAL OF NEUROSCIENCE (2006)
Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat
C Fiorentini et al.
MOLECULAR PHARMACOLOGY (2006)
Effects of sarizotan on the corticostriatal glutamate pathways
T Antonelli et al.
SYNAPSE (2005)
Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning
C Guigoni et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2005)
A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease
M Tomiyama et al.
NEUROSCIENCE RESEARCH (2005)
8-Hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease
LJ Mignon et al.
NEUROREPORT (2005)
Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors
T Carlsson et al.
BRAIN (2005)
Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia
C Guigoni et al.
JOURNAL OF NEUROSCIENCE (2005)
Increased D-1 dopamine receptor signaling in levodopa-induced dyskinesia
I Aubert et al.
ANNALS OF NEUROLOGY (2005)
DAncing past the DAT at a DA synapse
SJ Cragg et al.
TRENDS IN NEUROSCIENCES (2004)
Presynaptic mechanisms of motor fluctuations in Parkinson's disease:: a probabilistic model
R de la Fuente-Fernández et al.
BRAIN (2004)
Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsoman monkeys
AH Tahar et al.
NEUROBIOLOGY OF DISEASE (2004)
Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID study)
CW Olanow et al.
CLINICAL NEUROPHARMACOLOGY (2004)
Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease:: implications for dyskinesias
R de la Fuente-Fernández et al.
BRAIN (2004)
Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets
MJ Jackson et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2004)
Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function
E Bézard et al.
NATURE MEDICINE (2003)
Real-time decoding of dopamine concentration changes in the caudate-putamen during tonic and phasic firing
BJ Venton et al.
JOURNAL OF NEUROCHEMISTRY (2003)
Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease
M Lundblad et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2002)
Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models
F Bibbiani et al.
NEUROLOGY (2001)
Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies
E Bezard et al.
NATURE REVIEWS NEUROSCIENCE (2001)
Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature
JE Ahlskog et al.
MOVEMENT DISORDERS (2001)
Activation of 5-HT1A but not 5-HT1B receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation
K Kannari et al.
JOURNAL OF NEUROCHEMISTRY (2001)
Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease
CS Lee et al.
BRAIN (2000)
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
O Rascol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey
C Imbert et al.
JOURNAL OF NEUROSCIENCE METHODS (2000)
Share Paper
